Company will form broad-scale strategic partnerships with industry leaders in claims, EMR, formulary and provider-institutional data.
EVERSANA has announced partnerships with data and infrastructure companies, including Symphony Health and Compile, to create the industry’s first single, streamlined claims, formulary and physician dataset. The comprehensive, real-time view of the full healthcare system will drive EVERSANA’s end-to-end commercialization services to expedite and optimize targeting, access, adherence and valued outcomes, according to a company press release.
EVERSANA and Symphony Health, a provider of data, cloud-based analytics and consulting solutions to life science companies and healthcare organizations, finalized a multi-year relationship to provide access to real-time claims and electronic medical records data for more than 300 million patients. The data will be used to activate data-driven patient engagement and hub services to advance access and adherence at each stage of the product life cycle.
In addition to claims and EMR data, a partnership with Compile will further integrate physician data to drive market access and HCP engagement. By combining public, government and deep-web data with privately licensed medical and pharmacy claims data, Compile generates the ultimate system of record on every practitioner, facility, health system and event that takes place in the U.S. healthcare market. EVERSANA expects to announce a third partnership to integrate formulary data in the coming month.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.